# Pharmacological Receptor Mechanisms and Effects

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/pharmacological-receptor-mechanisms-and-effects/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers explores the role of sigma receptors, particularly the Sigma-1 receptor, in regulating cellular signaling, calcium signaling, cell survival, and their potential therapeutic implications in neuroprotection, neuropsychiatric disorders, cancer therapy, and neurodegenerative diseases. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t13047 |
| Works | 93 |

## Topic papers all

Showing 15 of 93.

- [Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China](https://scholariq.org/papers/risk-factors-associated-with-acute-respiratory-distress-syndrome-and-death-in/)
- [Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial](https://scholariq.org/papers/remdesivir-in-adults-with-severe-covid-19-a-randomised-double-blind-placebo/)
- [In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)](https://scholariq.org/papers/in-vitro-antiviral-activity-and-projection-of-optimized-dosing-design-of/)
- [Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis](https://scholariq.org/papers/comparative-efficacy-and-tolerability-of-15-antipsychotic-drugs-in-schizophrenia/)
- [Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic](https://scholariq.org/papers/psychiatric-and-neuropsychiatric-presentations-associated-with-severe/)
- [Potential Effects of Coronaviruses on the Cardiovascular System](https://scholariq.org/papers/potential-effects-of-coronaviruses-on-the-cardiovascular-system/)
- [Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients](https://scholariq.org/papers/early-remdesivir-to-prevent-progression-to-severe-covid-19-in-outpatients/)
- [1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study](https://scholariq.org/papers/1-year-outcomes-in-hospital-survivors-with-covid-19-a-longitudinal-cohort-study/)
- [Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19](https://scholariq.org/papers/hydroxychloroquine-with-or-without-azithromycin-in-mild-to-moderate-covid-19/)
- [A living WHO guideline on drugs for covid-19 (2020-2023)](https://scholariq.org/papers/a-living-who-guideline-on-drugs-for-covid-19-2020-2023/)
- [Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)](https://scholariq.org/papers/infectious-diseases-society-of-america-guidelines-on-the-treatment-and/)
- [Drug treatments for covid-19: living systematic review and network meta-analysis](https://scholariq.org/papers/drug-treatments-for-covid-19-living-systematic-review-and-network-meta-analysis/)
- [Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study](https://scholariq.org/papers/post-acute-covid-19-syndrome-incidence-and-risk-factors-a-mediterranean-cohort/)
- [Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.](https://scholariq.org/papers/cloning-and-functional-comparison-of-kappa-and-delta-opioid-receptors-from-mouse/)
- [Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19](https://scholariq.org/papers/hydroxychloroquine-in-nonhospitalized-adults-with-early-covid-19/)

## Topic primary papers

- [Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial](https://scholariq.org/papers/intravenous-methylprednisolone-pulse-as-a-treatment-for-hospitalised-severe/)
- [Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries](https://scholariq.org/papers/association-between-mental-health-disorders-and-mortality-among-patients-with/)
- [Trigeminal Pathways Deliver a Low Molecular Weight Drug from the Nose to the Brain and Orofacial Structures](https://scholariq.org/papers/trigeminal-pathways-deliver-a-low-molecular-weight-drug-from-the-nose-to-the/)
- [Low density of sigma1 receptors in early Alzheimer’s disease](https://scholariq.org/papers/low-density-of-sigma1-receptors-in-early-alzheimer-s-disease/)
- [Function of sigma1 receptors in Parkinson's disease](https://scholariq.org/papers/function-of-sigma1-receptors-in-parkinson-s-disease/)
- [Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations](https://scholariq.org/papers/safety-of-psychotropic-medications-in-people-with-covid-19-evidence-review-and/)
- [SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models](https://scholariq.org/papers/sa4503-a-sigma-1-receptor-agonist-suppresses-motor-neuron-damage-in-in-vitro-and/)
- [COVID-19 inpatients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry](https://scholariq.org/papers/covid-19-inpatients-with-psychiatric-disorders-real-world-clinical/)
- [Sigma-1 Receptor: A Potential Therapeutic Target for Traumatic Brain Injury](https://scholariq.org/papers/sigma-1-receptor-a-potential-therapeutic-target-for-traumatic-brain-injury/)
- [Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523](https://scholariq.org/papers/antidepressant-like-responses-to-the-combined-sigma-and-5-ht1a-receptor-agonist/)
- [Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020](https://scholariq.org/papers/analysis-of-covid-19-infection-and-mortality-among-patients-with-psychiatric/)
- [A Controlled Comparison of Fluoxetine and Amitriptyline in Depressed Out-patients](https://scholariq.org/papers/a-controlled-comparison-of-fluoxetine-and-amitriptyline-in-depressed-out/)
- [Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023](https://scholariq.org/papers/anti-sars-cov-2-pharmacotherapies-among-nonhospitalized-us-veterans-january-2022/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.